middle.news
How Race Oncology’s Drug Targets the ‘Undruggable’ MYC Oncogene
8:33am on Thursday 2nd of October, 2025 AEST
•
Healthcare
Read Story
How Race Oncology’s Drug Targets the ‘Undruggable’ MYC Oncogene
8:33am on Thursday 2nd of October, 2025 AEST
Key Points
Discovery that (E,E)-bisantrene targets G-quadruplex DNA and RNA, not like traditional anthracyclines
Mechanism inhibits critical cancer enzymes and downregulates MYC oncogene
Potential to refine clinical use and identify synergistic drug combinations
Enables biomarker development improving regulatory and commercial prospects
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE